Skip to main content
Clinical Trials/NL-OMON42466
NL-OMON42466
Completed
Not Applicable

A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple-dose subcutaneous and intravenous administration of OMS721 in healthy subjects - OMS721 MD SC and IV dose in HV

Omeros Corporation0 sites24 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
autoimmune diseases
Sponsor
Omeros Corporation
Enrollment
24
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • healthy volunteers
  • 18\-54 years, inclusive
  • BMI: 19\.0\-32\.0 kg/m2, inclusive

Exclusion Criteria

  • Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 0\.5 liters of blood in the 60 days prior the start of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials